News Sentiment

ABCL sentiment intelligence

Abcellera Biologics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.47 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-4.9% over one week, +16.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Abcellera Biologics, Inc. (8QQ) Q3 2025 Earnings Report - Results, Call & Slides

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.9% Price reacting lower
Trend fit Trend active 16.9% over four weeks
Fair value 62.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 20
Stock Titan 6
TradingView 5
Moomoo 4
simplywall.st 4
Simply Wall Street 3
Quartr 3
TipRanks 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 19
Analyst action 7
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Simply Wall Street Direct company coverage

AbCellera Biologics (ABCL) Could Be 22% Undervalued After Jazz Cancer Partnership

AbCellera Biologics (ABCL) is gaining attention after a preclinical collaboration with Jazz Pharmaceuticals to develop T cell engaging multispecific antibodies for gastrointestinal cancers. Despite a significant share price increase of 132.66% over the past year, analysts believe

Tone
Positive 73/100
Event
Deals and strategy
Published
30 Jun 2026 21:39
Source
Simply Wall Street